Phase II trial of gefitinib in recurrent glioblastoma.
By Jeremy N. Rich, D. Reardon, T. Peery, J. Dowell, J. Quinn, K. Penne, C. Wikstrand, Lauren B Van Duyn, J. Dancey, R. McLendon and 10 more. Journal of Clinical Oncology, 2004
761 citations recorded by the source corpus.
Subfields: Genetics, Molecular Biology, Oncology
View Paper: https://www.semanticscholar.org/paper/9229c34a28f46f6054988855211b88471d33bd5b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
In Molecular Biology
In Oncology
Citations in the corpus
- A Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates Inter- and Intra-tumoral Heterogeneity. (2019, background): “EGFR tyrosine kinase inhibition did not improve the overall survival of patients with glioblastomas (Rich et al., 2004; Uhm et al., 2011), but showed a survival benefit in patients with mutated EGFR in the absence of downstream PTEN mutation (Arif et al.”
- Malignant astrocytic glioma: genetics, biology, and paths to treatment. (2007, background): “Such efforts to stratify patients appear to be important in the optimal deployment of small molecule EGFR inhibitors as only a small fraction of GBM patients show meaningful responses to such agents (Rich et al. 2004; Lassman et al. 2005).”
- Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. (2005, neutral): “05 9 (1–84) PTEN expression 5/8 (62) 4/25 (16) 0.”
- Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme (2010, background): “In addition to these standard therapies, alternative therapeutic approaches have to some extent produced promising results or are the subject of ongoing investigations [20–25].”